Toward molecular imaging using spectral photon-counting computed tomography?

Molecular imaging is a valuable tool in drug discovery and development, early screening and diagnosis of diseases, and therapy assessment among others. Although many different imaging modalities are in use today, molecular imaging with computed tomography (CT) is still challenging owing to its low sensitivity and soft tissue contrast compared with other modalities. Recent technical advances, particularly the introduction of spectral photon-counting detectors, might allow overcoming these challenges. Herein, the fundamentals and recent advances in CT relevant to molecular imaging are reviewed and potential future preclinical and clinical applications are highlighted. The review concludes with a discussion of potential future advancements of CT for molecular imaging.

Automated summary

Molecular imaging plays a crucial role in drug discovery, disease screening, and therapy assessment. Despite challenges in utilizing CT for molecular imaging due to low sensitivity and contrast, recent advancements such as spectral photon-counting detectors show promise in overcoming these limitations. The review highlights potential future directions for advancements in CT molecular imaging.